Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

1626 results about "Immunologic disorders" patented technology

Pan-ras inhibitor compound

The present invention relates to a compound as shown in formula (A) having a pan-RAS inhibitory effect, or an isotopic derivative or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound, and the use of the compound of formula (A) in the prevention and / or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
Owner:ADLAI NORTYE BIOPHARMA CO LTD

KLRB1 binding agents and methods of use thereof

KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Bispecific chimeric antigen receptors targeting CD20 and BCMA

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.
Owner:ABELZETA INC

Compositions and methods for modulating immune response

In various embodiments, the disclosure provides compositions, such as polypeptides, polynucleotides, gene editing systems, small molecules, vectors, or host cells, comprising and / or modulating the expression or activity of an immunomodulatory-related protein. In various embodiments, the disclosure also provides methods of treating aging, senescence, fibrosis, autoimmunity, cancer, infection, and / or immune disease using agents comprising and / or modulating the expression or activity of an immunomodulatory-related protein, as well as methods of identifying the agents.
Owner:FLAGSHIP ENTREPRENEURSHIP & INNOVATION NO 7 CO LTD

Use of dual-target car-t cells in treating b-cell autoimmune diseases

The use of dual-target CAR-T cells in treating systemic lupus erythematosus and other B-cell autoimmune diseases is provided. The first target of the chimeric antigen receptor is CD19, the second target is BCMA, and specifically, the chimeric antigen receptor is a chimeric antigen receptor with a Loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ζ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.
Owner:GRACELL BIOTECHNOLOGIES (SHANGHAI) CO LTD

Antibodies with FC modifications and methods of using the same

The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.
Owner:THE GENERAL HOSPITAL CORP

Dosage forms for Tyk2 inhibitors

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.
Owner:BRISTOL MYERS SQUIBB CO

Inhibitors of RIPK2 and uses thereof

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I') or (X"): The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.
Owner:ODYSSEY THERAPEUTICS INC

AAV-based gene therapies for treatment of autoimmune diseases

Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV-based gene therapeutic regimen for treating and / or ameliorating autoimmune disorders such as multiple sclerosis. Further disclosed are nucleic acid segments encoding therapeutic polypeptides that have been codon-optimized for expression in human cells.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Monoclonal antibody targeting all subtypes of CD45 and application thereof

The invention discloses a monoclonal antibody targeting all CD45 subtypes and application of the monoclonal antibody, and belongs to the field of monoclonal antibody preparation. The hybridoma cell strain capable of stably secreting all anti-human CD45 subtype antibodies is successfully obtained by stably expressing short and long molecular subtypes of human CD45 extracellular regions in L929 mouse fibroblasts, immunizing BALB / c mice with L929 cells expressing the two molecular subtypes of human CD45, and fusing splenocytes with SP20 myeloma cells after the serum titer reaches the standard. And the monoclonal antibody targeting all subtypes of CD45 is obtained. The monoclonal antibody provided by the invention shows a high-affinity binding characteristic with all human CD45 molecular subtypes, has important application value in the aspect of human CD45 molecular detection, and can be used as a therapeutic antibody in the fields of tumor immunotherapy, autoimmune disease treatment, transplant rejection resistance and the like.
Owner:INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Thiazole derivative inhibitor, and preparation method therefor and use thereof

The present invention relates to a thiazole derivative inhibitor, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a compound, a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as an inhibitor in the treatment of autoimmune diseases.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Synthesis and use of novel proteolysis chimera compound targeting interleukin-1 receptor-associated kinase 4 (IRAK4)

The present invention relates to the technical field of chemical pharmacy, and in particular to a compound for degradation of a targeted interleukin-1 receptor-associated kinase 4 (IRAK4), and a pharmaceutically acceptable salt of the compound. The compound can be used for treating or preventing IRAK4-mediated immune diseases, inflammatory diseases, and cancers.
Owner:GAN & LEE PHARM CO LTD

KLRB1 binding agents and methods of use thereof

KLRB1 binding agents (in particular anti-KLRB1-antibodies and antigen binding portion thereof) with increased humanness and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells, (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Oxygen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof

The present invention relates to an oxygen-containing heterocyclic derivative inhibitor, and a preparation method therefor and a use thereof, and in particular to a compound, a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as an inhibitor in the treatment of autoimmune diseases.
Owner:SHANGHAI HANSOH BIOMEDICAL CO LTD +1

Synthetic peptide compounds and methods of use

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
Owner:REALTA HLDG LLC +2

BTK degrader

The disclosure includes compounds of any one of Formulae (0)-(5), (11)-(24), (A)-(E), and (1)-(V) comprising an E3 ubiquitin ligase binding moiety that binds an E3 ubiquitin ligase, as described herein. Also disclosed pharmaceutical compositions comprising compounds, and a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.
Owner:NEWAVE PHARMA INC

CCR6 receptor modulators

The present invention relates to compounds of Formula (I), their synthesis and use as CCR6 receptor modulators for the prevention or treatment of e.g. inflammatory / autoimmune diseases / disorders and cancer.
Owner:IDORSIA PHARMACEUTICALS LTD

Tyrosine Kinase Inhibitors

The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Owner:PRINCIPIA BIOPHARMA INC

Method for engineering transformation of cells by utilizing scar-free annular mRNA and application of method

The invention relates to a method for engineering transformation of cells by using scar-free annular mRNA and application of the method. Specifically, the present inventors make circular mRNA for in vitro and / or in vivo protein production based on a cyclization technique of a secondary structure of circular RNA. The annular mRNA does not contain any extra sequence except the target sequence, and is an accurate and efficient mRNA cyclization strategy, and the generated scar-free annular mRNA has the advantages of good stability, long half-life period, high protein expression total amount and the like, can be used for CAR and / or TCR related cell therapy, is especially suitable for in-vivo CAR generation cell therapy, and has a good application prospect. The compound has wide application in the field of clinical treatment of tumors, autoimmune diseases, infectious diseases and the like.
Owner:BYTERNA THERAPEUTICS LTD